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Abstract Based on their own experience and knowledge of
the literature, the authors review the pathobiological
characteristics of peripheral T-cell lymphomas (PTCLs),
focusing on the available prognostic indicators. The
International Prognostic Index (IPI), which is based on
age, performance status, lactate dehydrogenase [LDH],
stage, and extranodal involvement, appears to be efficient
as a prognostic index for PTCLs, at least in part and
especially for certain PTCL subtypes. However, it is not so
satisfactory for the two commonest PTCLs, PTCL not
otherwise specified (PTCL/NOS) and angioimmunoblastic
T-cell lymphoma (AITL), for which novel scores, possibly
based on the biologic features of the tumors, have been
explored. An Italian cooperative group proposed a revision
of the IPI for PTCL unspecified (PTCL-U), the Prognostic
Index for PTCL-U (PIT), which includes age, performance
status, LDH, and bone marrow involvement. The PIT
apparently offered some advantages, but they were not
confirmed in subsequent studies. A clinical-biological score
(the Bologna score) was then proposed, including tumor
proliferation and clinical features (age, LDH, and perfor-
mance status). This score appears promising and offers the
intriguing advantage of integrating biological and clinical
elements, but independent validation on a large series is still
warranted. More recently, gene expression profiling has
been used to identify novel molecular prognostic factors. In
particular, inactivation of the NFκBp a t h w a y ,h i g h
expression of proliferation-associated genes, and cyto-
toxic molecular phenotype seem to be associated with a
worse outcome. So far, however, none of these indicators
has been validated in an independent series. Finally,
various reports have dealt specifically with the prognos-
tication of NK-derived tumors, including nasal and nasal-
type lymphomas. Both the IPI and dedicated models
have turned out to be of prognostic relevance for these
tumors. In conclusion, although the IPI is somewhat
effective for PTCL prognostication, novel scores that are
more refined and possibly disease-specific are warranted.
The validation process for several models, including
clinical-pathological and molecular models, is now
ongoing.
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Introduction
In 1994, the Revised European-American Lymphoma
(REAL) Classification introduced new standards in the
lymphoma field [1]. In particular, it stated for the first time
that a classification of lymphoid tumors should comprise a
list of “real” entities, each defined by the amalgamation of
cell morphology, phenotype, molecular genetics, clinical
data, and identification of a normal counterpart, if possible
[1]. After a validation trial [2], the REAL Classification was
adopted by the World Health Organization (WHO) as
guideline for lymphoma diagnosis and therapy, and its
methodology was extended to all tumors of the hematopoi-
etic system [3￿￿]. Based on patients’ survival without any
treatment, non-Hodgkin lymphomas (NHLs) are classified
as indolent (survival measurable in years) or aggressive
(survival measurable in months).
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DOI 10.1007/s11899-010-0062-xPeripheral T-cell lymphomas (PTCLs) belong to the
aggressive lymphoma group [4￿￿]. They represent approxi-
mately 12% of all lymphoid neoplasms [4￿￿, 5￿￿]. Their
incidence varies in different countries and races, being
higher in HTLV-1 endemic areas (Asia, the Caribbean basin,
and some parts of the United States) [4￿￿, 5￿￿]. PTCLs are a
heterogeneous group of tumors that can be roughly
subdivided into specified and not otherwise specified
(NOS) forms [5￿￿, 6￿]. The NOS forms, corresponding to
about 60% to 70% of T-cell lymphomas, cannot be further
classified on the basis of morphology, phenotype, and
conventional molecular studies [4￿￿]. Usually, they occur in
the fifth or sixth decade of life, without sex predilection [7–
10]. Although PTCLs/NOS can present as isolated disease,
they more often have a widespread dissemination (stage III–
IV) with nodal, skin, liver, spleen, bone marrow, and
peripheral blood involvement [7–10]. B symptoms are
recorded in about 45% of cases at diagnosis. A hemopha-
gocytic syndrome may also be encountered [7–10].
The tumor morphology is highly variable, comprising
cells of different sizes and shapes [4￿￿]. PTCLs/NOS may
contain prominent reactive components, including small
lymphocytes, eosinophils, plasma cells, histiocytes, and
epithelioid elements [4￿￿].
Immunohistochemistry generally shows T-cell-
associated molecular expression, but the phenotypic profile
is aberrant in about 80% of cases [11].
Clonal rearrangements of T-cell receptor encoding genes
are generally detected [12]. The karyotype is aberrant in
more than 80% of patients and often is characterized by
complex abnormalities. However, specific alterations have
not been identified [13]. Recently, some recurrent lesions
have been documented by comparative genomic hybridiza-
tion and analysis of single-nucleotide polymorphisms
(SNPs) [14, 15].
On clinical grounds, PTCLs/NOS are among the most
aggressive NHLs. In most cases, the response to conven-
tional chemotherapy is indeed frustrating, with rates of
relapse-free and overall survival (OS) at 5 years less than
30% [5￿￿]. Notably, histologic classification remains a basic
prognostic indicator [5￿￿, 6￿, 8, 16]. Nodal and extranodal
entities are clinically distinct, as extranodal tumors,
especially the cutaneous forms, often have a relatively
good outcome [5￿￿]. In addition, among nodal PTCLs, the
distinction between anaplastic large-cell lymphoma
(ALCL) and other entities retains a significant prognostic
impact, as does the distinction between anaplastic lympho-
ma kinase-positive (ALK
+)a n dA L K
− cases among
ALCLs, [5￿￿, 6￿, 8, 16]. In fact, patients with ALK
+ ALCL,
particularly children and young adults, have a significantly
better clinical outcome than patients with all other forms
[5￿￿, 6￿]. Importantly, it was recently suggested that ALK
−
ALCL should be included in PTCLs/NOS, based on a lack
of evidence of clear biologic differences between them, but
new clinical and molecular findings have demonstrated that
ALK
− ALCL and PTCL/NOS are distinct entities, also
presenting with different clinical outcomes [6￿, 17￿￿, 18].
In addition to the basic distinction of the different
entities, several attempts have been made in recent years
to offer reliable prognostic indicators. Clinical, pathologi-
cal, clinical-pathological, and molecular scores have been
proposed and are briefly discussed in this article (Table 1).
International Prognostic Index (IPI)
The International Prognostic Index (IPI) was first intro-
duced in 1993 with the intent of identifying patients
affected by aggressive NHL, with its greater risk of
treatment failure, relapse, and death [19]. It is based on
clinical parameters, such as tumor stage, extranodal
localization, age, lactate dehydrogenase (LDH) level, and
performance status. It was largely based on B-NHL rather
than T-NHL, especially diffuse large B-cell lymphomas
(DLBCLs), but its ability to stratify PTCL patients was
reported in later years. In particular, the International
Lymphoma Study Group showed that OS and relapse-free
survival were significantly different in patients with low IPI
(0/1) versus high (4/5) IPI for all PTCL types except ALCL
(5-year OS, 36% vs 15%; 5-year failure-free survival, 27%
vs 10%) [2]. On the other hand, subsequent studies showed
that the IPI was particularly effective for prognostication in
both ALK
+ and ALK
− ALCL [6￿, 20]. In particular, in
ALK
+ ALCL, the 5-year OS was 94%±5% for the low/
low-intermediate risk group versus 41%±12% for the
high/high-intermediate group (P<0.0001) [20]. In fact, the
IPI was more relevant than ALK expression in stratifying
patients with ALCL: the relative risk of death was 3.50 for
the high/high-intermediate IPI group versus 0.29 for the
low/low-intermediate group, though both the IPI score and
ALK expression were significant prognostic factors [20].
In addition, in a large study within the International T-cell
Lymphoma Project (ITCLP), the IPI effectively identified
risk groups with different prognoses within both ALK
+
and ALK
− ALCL, although those with an IPI score of 3 or
more fell into the poor-risk category regardless of ALK
status [6￿].
Furthermore, Suzumiya et al. [21￿] recently reported on a
large series of patients with aggressive adult T-cell
leukemia/lymphoma (ATLL), providing evidence that IPI,
platelet count, and B symptoms were significant prognostic
factors. Interestingly, multivariate analysis indicated that
only the IPI was an independent predictor of OS in this
series, though the IPI prediction of OS was significant only
for the lymphoma type of ATLL (P=0.04), not for the acute
type (P=0.24) [21￿].
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expression of disease extension and the patient’s frailty. It
offers neither specific biologic hints nor potential targets for
overcoming drug resistance. It soon became clear that the
IPI was not as effective in PTCLs/NOS and angioimmuno-
blastic T-cell lymphomas (AITLs) (the two commonest
PTCL types) as in the original series of DLBCLs, probably
reflecting, at least in part, the fact that PTCL therapy is
basically derived from B-NHLs and specific trials have
been lacking for a long time. Thus, novel prognostic scores
for PTCLs have been investigated in the past few years.
Prognostic Index for PTCL/NOS
In 2004, an Italian group (Intergruppo Italiano Linfomi)
proposed a novel prognostic model based on a retrospec-
tive, multicentric clinical analysis of 385 patients with
PTCL unspecified (PTCL-U) [22]. The new model, the
Prognostic Index for PTCL-U (PIT), included bone marrow
involvement, age, performance status, and LDH. When
these four variables were combined in four groups, the PIT
could identify patient subgroups with different outcomes.
The PIT turned out to be slightly more effective than the IPI
in stratifying PTCL patients (log-rank 66.79 vs 55.94) and
was then proposed as reference tool. In addition, a
simplified, two-class PIT appeared to be superior to a
simplified two-class IPI (log-rank 49.36 vs 30.23) [22].
However, the PIT was based on a series lacking systematic
histologic review and, although its value was confirmed
within the International Peripheral T-Cell Lymphoma
Project (ITCLP), its results were not superior to those of
the IPI. In particular, the PIT was also applied to ALK
+ and
ALK
− ALCL and was similarly predictive of failure-free
survival and OS in both groups [6￿]. However, given that
the distribution of patients across the risk groups was very
similar with the two prognostic models and that bone
marrow involvement is rarely observed in ALCL, the PIT
actually seems to mirror the IPI in this setting [6￿]. In
addition, as it does not include tumor-specific biologic
factors, cannot be intended for the future application of
targeted therapies.
Clinical-Pathologic Prognostic Score (Bologna Score)
Immunohistochemical markers have been largely proposed
for prognostication of malignant lymphomas. In a large
collection of Italian PTCL cases, Went et al. [11] found that
high Ki-67 expression, positive Epstein-Barr virus (EBV)
status, and CD15 staining were associated with the worst
outcome in PTCL/NOS. Interestingly, EBV has repeatedly
Table 1 Prognostic markers and scores in peripheral T-cell lymphomas (PTCLs)
Prognostic indicator PTCL subtype Studies
Histotype All The Non-Hodgkin’s Lymphoma Classification Project [2]; Vose et al. [5￿￿];
Savage et al. [6￿]; Lopez-Guillermo et al. [8]; Ascani et al. [16]
International Prognostic
Index (IPI)
All The Non-Hodgkin’s Lymphoma Classification Project [2]
ALCL Savage et al. [6￿]; Falini et al. [20]
ATLL Suzumiya et al. [21￿]
NK/T-cell lymphoma Au et al [57￿]
PIT PTCL/NOS Gallamini et al. [22]; Savage et al. [6]
Bologna score PTCL/NOS, AITL Went et al. [11]; Briones et al. [34]
Korean prognostic index NK/T-cell lymphoma Lee et al. [54]
NK prognostic index NK/T-cell lymphoma Suzuki et al. [67]
EBV PTCL/NOS, AITL Went et al. [11]; Kluin et al. [24]; Dupuis et al. [25]
NK/T-cell lymphoma Au et al. [62]; Cheung et al. [60]; Chim et al. [64]; Huang et al. [65]; Lee et al. [66];
Ng et al. [63]
Proliferation index PTCL/NOS
Ki-67 Went et al. [11]
Molecular signature Cuadros et al. [43￿]
Cellular derivation PTCL/NOS Went et al. [11]
a; Bekkenk et al. [26]; Kojima et al. [27]; Iqbal et al. [48￿]
NFκB activation PTCL/NOS Martinez-Delgado et al. [36]; Ballester et al. [38]; Briones et al. [34]
CYP3A PTCL/NOS Rodríguez-Antona et al. [49]
AITL angioimmunoblastic T-cell lymphoma; ALCL anaplastic large-cell lymphoma; ATLL adult T-cell leukemia/lymphoma; NK natural killer;
PTCL/NOS peripheral T-cell lymphoma not otherwise specified
aPrognostic impact not statistically significant
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among both Asian and European patients [24, 25].
Specifically, Went et al. [11] found EBV positivity in 5%
of patients with PTCL/NOS and 3% of those with AITL,
values definitely lower than the value recorded by Dupuis
et al. [25] in a French PTCL cohort. Such discrepancies
may reflect geographic or racial differences. No other
immunohistochemical marker alone or in combination was
associated with a poor outcome, although patients with
tumors expressing CD57 or CD4
+/CD8
− phenotype showed
a tendency for a better outcome; the possible prognostic
relevance of the latter phenotype has also been proposed by
others [26, 27].
Furthermore, based on a large series provided with
follow-up data, Went et al. [11] developed a new score
integrating both patient-specific and tumor-specific charac-
teristics (age >60 years, performance status, LDH, and Ki-
67 protein ≥80%) and identifying three clearcut groups of
patients with different responses to therapy and differing life
expectancy(medianOS,37vs23vs6months; P<0.001)[11,
22, 28–33]. This score, the Bologna score, seemed to be
better able to predict patient outcome than previous
indices, including the IPI (P<0.001 vs 0.1) and PIT
(P<0.001 vs 0.0043). The prognostic ability of the
Bologna score was recently validated by a Spanish group
[34]. Remarkably, all the factors contributing to the
scoring system proposed by Went et al. [11], which
incorporates both patient-specific and tumor-specific char-
acteristics, are part of the routine workup, making their
integration simple and cost-effective.
Gene Expression Profiling
In the past few years, numerous studies have dealt with the
gene expression profiling (GEP) of nodal PTCLs [17￿￿, 18,
35–38, 39￿￿, 40￿￿, 41, 42, 43￿, 44–47, 48￿], possibly
providing novel insight into PTCL prognostication. First,
a few reports suggested that PTCLs/NOS may present with
upregulation or downregulation of NFκB molecules [35,
36, 38], with possible prognostic relevance [36, 38]. In
particular, cases with lower levels of NFκB-related mole-
cules or other evidence of NFκB inactivity showed better
survival, with a median OS of 25 months (range 0–
124 months) versus a median OS of 12 months (range
0–19 months) (P=0.032) [36, 38]. This observation was
confirmed by another Spanish group, which demonstrated
5-year OS of 45% in NFκB
+ cases versus 0% in NFκB
−
cases (P=0.04) [34]. However, all these studies included a
relatively limited number of cases, mixed different histo-
types [34, 36], or included patients with prominent non-
neoplastic components [38], which may have influenced the
results, at least in part.
In addition, based on GEP obtained from 35 patients
with nodal PTCL (23 with PTCL/NOS and 12 with AITL),
it was suggested that overexpression of genes involved in a
“proliferation signature” was associated significantly with
shorter survival [43￿]. This proliferation signature included
genes commonly associated with the cell cycle, such as
CCNA, CCNB, TOP2A, and PCNA [43￿]. Notably, this
evidence of high proliferation as a possible adverse
prognostic factor was definitely in line with the findings
of Went et al. [11] and the ITCLP (unpublished),
highlighting the importance of this parameter.
Finally, based on GEP analyses, our group indicated that
PTCLs/NOS can be subclassified on the basis of histogen-
esis. In particular, at least two subgroups were described,
derived from activated helper elements and cytotoxic
elements [17￿￿]. This finding was recently confirmed by
Iqbal et al. [48￿]. Intriguingly, this report also suggested
that the cytotoxic profile may be associated with unfavor-
able outcome, though this evidence was based on a limited
series and warrants further validation. On the other hand,
the possibility of more favorable outcome for PTCL cases
with a helper phenotype has been previously suggested by
others [11, 26, 27].
Overall, GEP studies have provided evidence that
molecular features may be useful in defining the prognosis
of PTCL patients. However, no complete explanation has
been offered regarding the molecular basis of drug
resistance. Our group described for the first time the
expression of molecules associated with drug resistance in
solid tumors, such as CYR61 and NNMT in PTCL/NOS
[17￿￿]. Furthermore, Rodríguez-Antona et al. [49] recently
found that a high expression of cytochrome P450 3A
(CYP3A), an enzyme involved in the inactivation of
chemotherapy drugs, was associated with poor response to
standard PTCL chemotherapy, suggesting that CYP3A
could be useful as a predictor of response. Indeed, the
molecular classification of PTCLs and the identification of
key events in their molecular pathology is likely to be the
basis for future prognostication and targeted treatment in
this field, as has occurred in DLBCL [50, 51￿￿].
Prognostication of NK/T-Cell Lymphoma, Nasal Type
Extranodal natural killer (NK)/T-cell lymphoma, nasal type
is a distinct entity in the WHO classification of lymphoid
tumors; it is more frequent in Asia and in Central and South
America than in Western countries [52–56, 57￿]. Morpho-
logically, tissue invasion, vascular destruction, and necrosis
are the most prominent features; EBV is always integrated
in the genome of neoplastic cells [56]. Most cases derive
from NK cells and are characterized by a typical NK
phenotype and T-cell receptor genes in germ-line configu-
ration, but in some instances a cytotoxic T-lymphocyte
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upper aerodigestive tract (nasal NK/T-cell lymphoma) are
the most commonly involved sites, but skin, the gastroin-
testinal tract, lung, testis, and soft tissues (extranasal NK/
T-cell lymphoma) can be also affected [52, 53, 56, 58].
The prognosis of extranodal NK/T-cell lymphoma is
poor, the worst among the PTCL categories [57￿]. The
survival rate is 30% to 40%, with some differences between
nasal and nonnasal disease; the nonnasal disease is more
aggressive [56, 57￿, 59]. The inclusion of radiotherapy in
treatment protocols has improved the outcome of nasal
NK/T-cell lymphoma in stage I or II [55, 56, 57￿, 60, 61].
Among nasal forms, adverse prognostic factors are
unfavorable IPI, advanced-stage disease (stage III or IV),
high circulating EBV DNA levels, and detection of EBV
in bone marrow cells by in situ hybridization [56, 57￿, 60,
62–66]. Some studies suggest that a high proportion of
large/transformed cells in the tumoral population has a
negative impact on survival, but the significance of
cytologic features as a prognostic indicator is still
uncertain [55, 56, 57￿, 58]. Primary extranasal cases are
highly aggressive and the response to therapy is poor even
in patients with localized disease [56, 57￿].
A Korean group has proposed a new prognostic index
specifically developed for NK/T-cell tumors, based on four
parameters: B symptoms, LDH levels, stage, and regional
lymph node involvement. This index demonstrated better
prognostic stratification of NK/T-cell lymphomas than the
IPI [54].
In addition, a recent study showed that four factors
(nonnasal type, stage, performance status, and extranodal
involvement) were significant prognostic factors in NK/T-
cell lymphomas [67]. Using these four variables, an NK
prognostic index was successfully constructed in which the
4-year OS was 55% for patients with no adverse factors,
33% with one adverse factor, 15% with three factors, and
6% with four factors [67].
Conclusions
PTCLs have long represented an orphan pathology, as
explained by their relatively low incidence (though higher
than the incidence of a “common” tumor such as Hodgkin’s
lymphoma), the difficulties encountered in their analysis,
and their dismal prognosis. During the past few years,
however, a great deal of interest has developed and new
light has been shed on the pathobiology of these tumors,
and leading to the proposal of more effective prognostica-
tors. Although the IPI is somewhat effective for PTCL
prognostication, more refined and possibly disease-specific
novel scores have been explored. Several models including
clinical-pathological and molecular features have been
proposed and are now being validated. In addition,
innovative therapeutic schedules have been proposed on
the basis of newly developed microarray techniques. We
seem close to the morning of a new era in which the
shadows that have wrapped PTCLs for several decades will
be dissipated.
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